Skip to main content
Top
Published in:

Open Access 09-05-2024 | Semaglutide | Original Research

Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide

Authors: Caroline Swift, Monica S. Frazer, Noelle N. Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone, Mico Guevarra

Published in: Diabetes Therapy | Issue 7/2024

Login to get access

Abstract

Introduction

The treatment landscape for type 2 diabetes mellitus (T2DM) is complex and constantly evolving, and real-world evidence of prescribing patterns is limited. The objectives of this study were to characterize lines of therapy (LOTs), calculate the length of time spent on each LOT, and identify the reasons for the LOT end among patients who initiated oral semaglutide for T2DM.

Methods

This retrospective, claims-based study included commercial and Medicare Advantage adults with T2DM. Data from November 1, 2019, and June 30, 2020, were obtained from Optum Research Database. Patients with ≥ 1 claim for oral semaglutide and continuous health plan enrollment for ≥ 12 months prior to (baseline period) and ≥ 6 months following (follow-up period) the date of the first oral semaglutide claim were included. LOT 1 began on the date of the first oral semaglutide claim. The start date of any subsequent LOTs was the date of the first claim for an additional non-insulin anti-diabetic drug class or a reduction in drug class with use of commitment medications. The LOT ended at the first instance of medication class discontinuation, change in regimen or end of follow-up.

Results

Of the 1937 patients who initiated oral semaglutide, 950 (49.0%) remained on their initial regimen over the 6-month follow-up period, 844 (43.6%) had at least one subsequent LOT, and 89 (4.6%) had at least two subsequent LOTs. Among patients with more than one LOT, approximately 20%–25% used oral semaglutide as monotherapy or combination therapy during LOTs 2 and 3. Metformin was frequently used during treatment across all LOTs.

Conclusion

This study provides insight for physicians and payers into the real-world prescribing practices within the first 6 months following oral semaglutide initiation and fills the gap in understanding the frequency of regimen changes in the constantly evolving and complex environment of T2DM care.
Literature
26.
go back to reference Helseth LD, Susman JL, Crabtree BF, O’Connor PJ. Primary care physicians’ perceptions of diabetes management. A balancing act. J Fam Pract. 1999;48(1):37–42.PubMed Helseth LD, Susman JL, Crabtree BF, O’Connor PJ. Primary care physicians’ perceptions of diabetes management. A balancing act. J Fam Pract. 1999;48(1):37–42.PubMed
29.
go back to reference Feingold KR, et al. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth, MA: MDText.com Inc.; 2000. Feingold KR, et al. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth, MA: MDText.com Inc.; 2000.
30.
35.
go back to reference Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of clinical preventive services. J Fam Pract. 1994;38(2):166–71.PubMed Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of clinical preventive services. J Fam Pract. 1994;38(2):166–71.PubMed
Metadata
Title
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Authors
Caroline Swift
Monica S. Frazer
Noelle N. Gronroos
Andrew Sargent
Michael Leszko
Erin Buysman
Sara Alvarez
Tyler J. Dunn
Josh Noone
Mico Guevarra
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 7/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01589-4

Other articles of this Issue 7/2024

Diabetes Therapy 7/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare